LoadingLoadingCookies show us what works. Privacy
Cookies show us what works. Privacy
LoadingCookies show us what works. Privacy
38 funds hold it · Insiders net buying
Net buying: insiders sold $0 and bought $100K on the open market in 90 days (SEC Form 4). Congress: net selling of $90K to $323K in 180 days.
Analyst target and ratings are on paid plans
Unlock the full resultsLast report
Oct 28, 2026
Financial period
third quarter 2026
Earnings per share
$0.72 expected
Revenue
$5.05B expected
| Quarter / reported | Earnings per share | Beat or miss | Revenue / income | Revenue vs last year |
|---|---|---|---|---|
| Sep 30, 2026Reported Oct 28, 2026 | $0.73est. $0.72 | +0.94%in line | $5.14Best. $5.05B+1.66% | +1.4%from $5.07B |
| Jun 30, 2026Reported Jul 29, 2026 | $0.86est. $0.83 | +3.86%beat | $5.44BCompany release | +7.5%from $5.06B |
| Mar 31, 2026Reported Apr 22, 2026 | $0.80est. $0.79 | +1.62%beat | $5.20BSEC filing | +11.6%from $4.66B |
| Dec 31, 2025Reported Feb 4, 2026 | $0.80est. $0.78 | +2.43%beat | $5.29BAlpha Vantage | +15.9%from $4.56B |
| Sep 30, 2025Reported Oct 22, 2025 | $0.75est. $0.71 | +5.63%beat | $5.07BSEC filing | +20.3%from $4.21B |
| Jun 30, 2025Reported Jul 23, 2025 | $0.75est. $0.73 | +2.74%beat | $5.06BSEC filing | +22.8%from $4.12B |
| Mar 31, 2025Reported Apr 23, 2025 | $0.75est. $0.67 | +11.94%beat | $4.66BSEC filing | +20.9%from $3.86B |
| Dec 31, 2024Reported Feb 5, 2025 | $0.70est. $0.66 | +6.06%beat | $4.56BAlpha Vantage | +22.4%from $3.73B |
Earnings per share comes from Yahoo Finance where available, then Alpha Vantage or the company release. Revenue comes from company releases, SEC filings, Alpha Vantage or Yahoo Finance. A beat or miss needs an analyst estimate on the same basis as the reported figure, so quarters without one show none. Non-USD amounts carry their currency code.
| USD | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $5.29B | $5.20B | $5.44B | $5.14B |
| Cost of what it sold | $1.35B | $1.59B | $1.59B | $1.71B |
| Gross profit | $3.94B | $3.61B | $3.85B | $3.43B |
| What it spent | ||||
| Research and development | $569.0M | $516.0M | $554.0M | $520.0M |
| Sales and admin | $1.83B | $1.78B | $1.80B | $1.68B |
| Other operating costs | $328.0M | $244.0M | $313.0M | $246.0M |
| Total operating expenses | $2.73B | $2.54B | $2.67B | $2.45B |
| What was left | ||||
| Operating profit | $1.21B | $1.07B | $1.18B | $979.0M |
| Interest on debt | $90.0M | $90.0M | $96.0M | $100.0M |
| Profit before tax | $700.0M | $1.16B | $1.06B | $733.0M |
| Tax | $31.0M | -$176.0M | $155.0M | $153.0M |
| Net profit | $668.0M | $1.34B | $907.0M | $578.0M |
| EBITDA | $1.16B | $1.60B | $1.51B | $979.0M |
This stock's price action is mixed.
Trend
Mixed
55 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
Coverage leans bullish
Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
NeutralNov 10Boston Scientific Corp. stock outperforms competitors on strong trading day
BullishNov 10Medtronic PLC stock underperforms Tuesday when compared to competitors
NeutralNov 10Sensus Healthcare Announces Sale of 1,000th SRT System, Marking Significant Commercial Milestone
Leans bullishNov 10Eocene's Colospan unit signs first European deal for CG-100 device
NeutralNov 10Orthofix Q3 Revenue Misses Estimates by $2.62 Million as EPS Beats
Leans bearishNov 10RadNet Q3 2026 Earnings Call Transcript
Leans bullishNov 9Stryker stock faces lower 2026 outlook after Q3 earnings miss
NeutralNov 934 macro signals shaping BSX right now
Unlock sector rotation, regime shifts, and macro event windows tied to this stock.
Unlock the full results
